公司概覽
業務類別 Biotechnology
業務概覽 Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
公司地址 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
電話號碼 +1 617 551-8200
傳真號碼 +1 617 551-8101
公司網頁 https://www.alnylam.com
員工數量 2500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Kevin Joseph Fitzgerald, PhD Executive Vice President, Chief Scientific Officer and Head, Early Research and Early Development 美元 586.60K 24/03/2025
Dr. Yvonne L Greenstreet, MB.Ch.B. Director and Chief Executive Officer 美元 1.25M 12/02/2026
Mr. Jeffrey V. Poulton Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 687.40K 12/02/2026
Dr. Pushkal P. Garg, M.D. Chief Medical Officer and Executive Vice President, Development and Medical Affairs 美元 682.10K 24/03/2025
Mr. Tolga Tanguler Chief Commercial Officer 美元 627.40K 24/03/2025
 
董事會成員
董事會 職務 更新日期
Dr. Elliott Sigal, M.D.,PhD Independent Director 12/02/2026
Dr. Margaret A. Hamburg, M.D. Independent Director 12/02/2026
Dr. Phillip A. Sharp,PhD Independent Director 05/03/2025
Mr. Stuart A. Arbuckle Independent Director 12/02/2026
Ms. Amy W. Schulman Chairman of the Board 12/02/2026
Dr. Yvonne L Greenstreet, MB.Ch.B. Director and Chief Executive Officer 12/02/2026
Mr. David E.I. Pyott, M.A.,M.B.A. Independent Director 12/02/2026
Dr. Dennis A. Ausiello, M.D. Independent Director 12/02/2026
Dr. Olivier Raymond Brandicourt, M.D. Independent Director 12/02/2026
Mr. Peter N. Kellogg Independent Director 12/02/2026
Ms. Colleen F. Reitan Independent Director 12/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:28)
代號 名稱 佔比% 持有日期
VOTVanguard Mid-Cap Growth ETF0.83%31/01/2026
IBBiShares Biotechnology ETF0.73%28/02/2026
CGGRCapital Group Growth ETF0.53%31/01/2026
IWFiShares Russell 1000 Growth ETF0.39%28/02/2026
QQQMInvesco NASDAQ 100 ETF0.38%27/02/2026
IWRiShares Russell Mid-Cap ETF0.36%28/02/2026
VHTVanguard Health Care ETF0.30%31/01/2026
JEPQJPMorgan Nasdaq Equity Premium Inc ETF0.22%27/02/2026
SCHGSchwab US Large-Cap Growth ETF™0.19%28/02/2026
XBIState Street® SPDR® S&P® Biotech ETF0.18%27/02/2026
USMViShares MSCI USA Min Vol Factor ETF0.17%28/02/2026
FBTFirst Trust NYSE Arca Biotech ETF0.15%26/02/2026
VONGVanguard Russell 1000 Growth ETF0.15%31/01/2026
JGROJPMorgan Active Growth ETF0.12%27/02/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.12%28/02/2026
VVVanguard Large-Cap ETF0.12%31/01/2026
SCHXSchwab US Large-Cap ETF™0.10%28/02/2026
FMDEFidelity Enhanced Mid Cap ETF0.09%27/02/2026
TQQQProShares UltraPro QQQ0.09%27/02/2026
VTVanguard Total World Stock ETF0.07%31/01/2026
 1    2    3    4    5    6    7    8    9    10    11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.